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ABSTRACT Helixloop-helix proteins play important
roles in developmental processes, such as myogenesis, neuro-
genesis, and sex determination. The gene Enhancer of split
(E(spJ of Drosophila, a member of a gene complex that is
involved in early neurogenesis, encodes a protein with a basic
domain and a helixloop-helx motif. We took advantage of a
dominant mutation of this gene, E(spl)D, to define in vivo
structural features of this protein for proper function. The
mutation renders the otherwise recessive eye phenotype of spi
dominant. By germ-line transformation of different in vitro
mutagenized versions of the E(spl) gene, we could demonstrate
that the basic domain of this helix-oop-elx protein is func-
tional and necessary for expression of thedo t phenotype.
These results are supported by in vitro DNA-binding assays,
which showed that the basic domain is in fact necessary for
DNA binding, despite the presence of a proline residue. Fur-
thermore, we could show that the dominant enhancement of spi
is caused by truncation of the E(SPL)D protein in combination
with deletion of a putative regulatory element.
The gene Enhancer of split [E(spl)] of Drosophila is part of a
gene complex [E(SPL)-C, the function of which is required
for control of the binary decision between neural and epi-
dermal cell fates in uncommitted cells of the neurogenic
ectoderm (1). Results of genetic and cell transplantation
experiments suggest that E(SPL)-C is a key element in
establishment of epidermal commitment of neuroectodermal
cells (2, 3). Seven members of this complex, including the
E(spl) gene, encode proteins characterized by basic and
helix-loop-helix domains (the bHLH motif) (ref. 4; E.K., H.
Schrons, F. Grawe, and J. A. Campos-Ortega, unpublished
data), suggesting a function in DNA binding and transcrip-
tional regulation. bHLH proteins have been found in many
organisms, ranging from yeast (5, 6) and plants (7) to animals,
and some of them are of crucial importance for control of
developmental pathways, such as myogenesis or neurogen-
esis (see refs. 1, 8, and 9 for reviews). The common charac-
teristic of these proteins is their suggested DNA-binding
capacity, mediated by the bHLH domains (10), and in several
cases bHLH proteins have been shown to act as transcrip-
tional activators (e.g., see refs. 11-13). The HLH domain is
required for dimerization, which is a prerequisite for DNA
binding, whereas target specificity is mediated by the basic
domain, which lies adjacent to the HLH motif(14, 15). Unlike
most other bHLH proteins, the E(SPL) protein and the other
six bHLH proteins of the E(SPL)-C complex each contains
aproline residue in its basic domain (ref. 4; E.K., H. Schrons,
F. Grawe, and J. A. Campos-Ortega, unpublished data),
which, in the case of MyoD (15), has been reported to be
incompatible with DNA binding. Thus, the DNA-binding
capabilities of the E(SPL)-C products are open to question.
In many instances, conclusions drawn from in vitro DNA-
binding assays suffer from the drawback that no in vivo test
is available to prove the relevance of the observed effects for
the organism or the cell itself. In the case of the E(spl)D
mutation, a dominant mutation of the gene E(spl), we have an
ideal tool in hand with which to study both in vivo and in vitro
the effects of modifications of the gene. This mutation
renders expression of the otherwise recessive phenotype of
split (sp), an allelomorph of the neurogenic gene Notch (N),
dominant (16-19). N encodes a transmembrane protein with
36 epidermal growth factor (EGF)-like repeats in the extra-
cellular domain and is involved in receiving the lateral
inhibition signal that suppresses the neural and allows the
epidermal fate in cells of the neurogenic ectoderm. Further-
more, N is involved during several other processes that
require cell fate choices-e.g., development ofthe sensilla or
the compound eye. The recessive spi mutation is due to a
single amino acid exchange in one of the EGF-like domains
and leads to development of fewer and split bristles (hence
the name) and failure of the photoreceptor cells to form
proper ommatidial clusters (for recent review, see ref. 20 and
references therein). In combination with E(spl)D, the latter
phenotype is particularly enhanced and is accompanied by
severe cell death (19).
The E(spl)D chromosome carries lesions in two genes, two
deletions, one within and one upstream of the gene E(spl)
(which corresponds to transcription unit m8), and an inser-
tion in the adjacent gene groucho (gro; transcription unit
m9/mlO) (refs. 4, 21, and 22; Fig. 1A). We have previously
shown by germ-line transformation that the ability to enhance
the split phenotype is associated with the mutant E(spl)D gene
(ref. 4; Fig. 2C). Here we used the mutant gene as well as
several in vitro mutagenized versions to demonstrate the
importance ofthe basic domain for the enhancing effect ofthe
spl phenotype, and we confirmed these results by in vitro
DNA-binding experiments. Furthermore, we established a
causal relationship between molecular lesions in the E(spl)D
gene and the dominant phenotype.
MATERIALS AND METHODS
Drosophila Stocks. Flies were maintained according to
standard laboratory procedures. All crosses were performed
at room temperature or at 250C. OregonR was used as wild
type; for description of balancer chromosomes and markers
see refs. 23 and 24. The following alleles of E(SPL)-C were
used: grow (mutant for gro; ref. 25), grorY78-rl711 (deficient
for gro and other complementation groups distal to it; H.
Schrons, E.K., and J. A. Campos-Ortega, unpublished data),
E(spl)D (16), P[(w+) m8D; T18.2], and P[(w+) m8D; T18.3] (4).
Abbreviation: bHLH, basic domain and helix-oop-helix motif.
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FIG. 1. The genes E(spl) and gro in wild type and E(spl)D. (A) Part
of the genomic region of the E(SPL) complex with the defects
mapped in the E(spl/D chromosome (4, 21, 22). Dotted lines indicate
deletions or insertions relative to wild-type DNA. All EcoRI sites
(arrowheads) but only some of the other restriction sites (B, BamHI;
Bg, Bgl II; C, Cla I; S, Sal I; X, Xho I) are shown. Map units in
kilobases (kb) are according to ref. 21. Arrows, transcription units;
solid bars, fragments used for transformation. In the E(spl)D chro-
mosome, the gene gro carries a 5-kb insertion of a middle repetitive
element in an intron. Furthermore, two deletions have been mapped,
one 5' to the E(spl)D gene and the other at the 3' end of its
transcription unit. (B) Organization of the predicted E(SPL) and
E(SPL)D protein products. Solid lines, genomic DNA; thick lines,
wild-type DNA; thin lines, DNA from E(spl/L; broken lines, dele-
tions. Bars, putative translation products with basic domain (solid)
and HLH domain (stippled). The predicted E(SPL)+ and E(SPL)D
proteins are identical up to the breakpoint of the deletion, but in the
E(SPL)D protein the 56 C-terminal amino acids, including a con-
served tetrapeptide (WRPW), are deleted and replaced by a different
nine-amino acid sequence (hatched) (4).
Construction of Plasmids. m8 and m8D constructs were
subcloned as Cla I fragments from genomic clones (map units
10.7-13.8, according to ref. 21; see also Fig. 1) into the
Bluescript vector (Stratagene) and cloned as Pst I/Kpn I
fragments (using the restriction sites of the polylinker) into
the transformation vector pW8 (26). To produce the recom-
binant inserts m8+/D and m8D/+, we used the Xho I site at
nucleotide 3523 (4). For the m9,mJOD construct, phage clones
were isolated from a genomic library made from E(spl)DDNA
in the EMBL-4 phage vector (27). Two fragments from two
different phages, a Bgi II (map unit 13.1)/BamHI (site within
the inserted DNA) fragment and a BamHI/Sal I (map unit
21.9) fragment (map units according to ref. 21) were fused to
build a complete m9,mJOD fragment (Fig. 1A).
In Vitro Mutagenesis. In vitro mutagenesis essentially fol-
lowed the method described in ref. 28, with modifications as
described by the supplier of the system (Amersham). Primers
used are summarized below, numbering (in parentheses) is
according to ref. 4, << indicates primers in antisense orien-
tation. Nucleotide sequences that do not correspond to wild
type are underlined, nucleotides in boldface represent intro-
duced Kpn I restriction sites used for cloning or introduced
stop codons. In vitro mutagenesis was confirmed by sequenc-
ing, using the chain-termination method (29), or by testing for
the newly introduced restriction site, followed by sequenc-
ing. For construction of m8+ del, two Kpn I sites were
introduced into the m8+ construct at the borders of the
desired deletion by in vitro mutagenesis, using the primers
CTACAAGAACTTGGTACCATTCCACGAAGC (nucleo-
tides 3717-3746) and GGAAATCTATTTTGGTACCGAC-
CGAGTTG (nucleotides 4200-4228). After removing the
fragment between the two Kpn I sites, the remaining Kpn I
site was eliminated by further in vitro mutagenesis, using
primer GCGTCTACAAGAACTTGGCAATGACCGAGT-
TGA (nucleotides 3713-3729 and 4214-4229). The nucleo-
tides at positions 4225 and 4226 of this construct are the same
as in the m8D gene, thus leading to the same nine-amino acid
sequence as in the dominant mutation. For construction of
m8+.Stop, different termination codons were used: AA-
GAACTTGTAGCAATTCCA (nucleotides 3721-3740),
CAAGAACTTGIAACAATTCCAC (nucleotides 3720-
3741), and CTACAAGAACTTGIAAIAATAACACGAAG-
CACAG (nucleotides 3717-3750). For the remaining con-
structs, the following primers were used: for m8DstOP, CTCG-
GTCATTIACAAGTTCTTG (nucleotides <<4229-4214
and <<3729-3719); for m8D~bd-, CACTTGTTCATGTCG-
GCAAGTAGCTGG2CCACCAG-CATTGGC (nucleotides
<<3446-3405); for m8DPT, CCAGCATTGICTTCT-
TCACC (nucleotides <<3415-3396); for m8D PN, CGCTC-
CAGCATGTTCTTCTTCACCTTCTGG (nucleotides
<<3419-3390). The same primers were used to create the
corresponding mutations in the wild-type construct.
Germ-Line Transformation. Germ-line transformation ex-
periments were carried out essentially as described (30),
using the transformation vector pW8 (26). Transposase was
supplied either by coinjection of the A2-3 helper plasmid (31)
or by using wiw; A2-3/A2-3 embryos as hosts (32). Trans-
FIG. 2. Effects of different constructs on the eye phenotype of spi/+ females. (A) y w spl/+. Note the regular, wild-type patterning of the
ommatidia. (B) y w spl/+; E(spl)D/+. Although the spi mutation also affects bristle development, we analyzed only the effect of E(spl)0 and
the different transgenes on the eye phenotype. As the spi phenotype is variable and easily affected by modifying influences, we assayed the
effects of our constructs in heterozygous females, which themselves display a wild-type, regularly spaced ommatidial pattern (A). The spI
phenotype, however, becomes dominant in an E(spl)D/+ background (B); this effect is referred to in the text as spi enhancement. (C) y w spl/+;
P[(w+)m8D E6.1]/+. The fragment encoding the E(SPL)D protein (see Fig. 3b) enhances the spi phenotype to nearly the same extent as the
original mutation. (D) y w spl/+; P[(w+)m8+.StOPSt25.1I/+. This construct encodes a truncated E(SPL)+ protein (see Fig. 3f), which does not
lead to an enhancement of the spl phenotype when present in one copy. (E) y w spl/+; P[(w+)m8+.s'OPSt25.1]/P[(w+)m8+ StOPSt25.1I. The same
construct as in D results in a distinct enhancement when present in two copies, although the degree of enhancement is not as strong as with
the m8D construct (see C).
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FIG. 3. Different m8+ and m8D constructs and their el
spl phenotype. Shown are various Cla I fragments (see
drawn to scale). Thick lines, wild-type DNA; thin lines,
E(spl)D; broken lines, deletions. +1, Putative transcriptic
Bars, translation products with the basic region (solid)
domain (stippled), and the nine-amino acid sequence ad(
terminus of the E(SPL)D protein (hatched). Parts of t
proteins that were eliminated by the introduction of a
codon are indicated (x). The amino acid sequence c
domains is as shown in a for the wild type, except in h-j,
been mutated (altered amino acids are in boldface and i
Assessment ofthe degree ofspl enhancement. E(spl) is cI
by (i) smaller eyes and (ii) rough eyes. As in wild-type a
the number of ommatidia varies considerably (with a (
15%), which makes it an unsuitable criterion for estim
degree ofenhancement, we used the roughening ofthe e5
reliable measure. This is caused by an irregular arrange
ommatidia due to a loss of their hexagonal array. +, Stroi
ment of the spI phenotype, with no continuous lines of
left. For example, although the size of the eyes in Fig
differs, the roughening is the same. -, No enhancement;
enhancement can be detected only when the construct i
two copies (compare Fig. 2 D and E). In this case, some
are still aligned, which results in a weaker roughening. T
the degree of spI enhancement, all transgenic lines ob
each construct were evaluated (for numbers of lines
Materials and Methods). In principle, the same result -
in each case. (a and b) Cla I fragments as in Fig. 1A,
protein of 179 amino acids (a) and 132 amino acids (b),
the wild type plus nine new amino acids (hatched box
Recombinant fragments m8D/+ and m8+/D, encoding a D
and a truncated protein with the nine additional amino
shown in b. (e) For the construction of m8+'del, two Kpn
introduced into the m8+ construct at the borders of
deletion, and, after removing the fragment between the
sites, the remaining Kpn I site was eliminated. The C-te
spl genic stocks were established over the appropriate balancers
enhance- or were kept as homozygotes.
ment Numbers of lines obtained were as follows: m9,10D, 2;
w- m8+, 4; m8D, 1; [in addition to two lines previously described
(4)]; m8D/+, 3; m8+/D, 5; m8+ StOP (TAG, 6; TAA, 6; TAA-
TAATAA, 10), m8Dstops 6; m,+8del, 9; m8+,bd- 5; m8+,P-T, 7;
+ m+,P-N, 3; m8Dbd, 11; M8DP-T, 8; m8DP-N, 6.
Electrophoretic Mobility-Shift Assays. For construction of
expression vectors, the coding regions of the different con-
structs shown in Fig. 3 were amplified by PCR, using primers
- at positions 3361-3379 and 3889-3907 for the wild-type
protein and its derivatives and primers at positions 3361-3379
and 4221-4241 for the E(SPL)D protein (numbered according
+ to ref. 4). The fragments were cloned into the BamHI site ofthe pET-3a expression vector (41). Transformation, induc-
tion, and purification of proteins were performed according
to ref. 42. The protein was purified by sequential detergent
+ washes of the insoluble inclusion bodies. The final pellet was
solubilized in a buffer containing 5M urea, and, after dialysis,
aliquots were analyzed by SDS/polyacrylamide gel electro-
- * phoresis. A double-stranded oligonucleotide (top strand,
5'-GATCACGCCACGAGCCACAAGGATTG-3'; bottom
strand, 5'-GATCCAATCCTTGTGGCTCGTGGCGT-3')
was labeled at both ends by filling in with Klenow fragment
-+ in the presence of [a-32P]dATP to a specific activity of5 x 106
cpm/,ug. Protein-DNA complexes were formed by incuba-
tion of 0.5 ,&g of protein with 1.5 ng (7500 cpm) of labeled
-- oligonucleotide in 10 ul of buffer [25 mM Hepes-KOH, pH
7.5/100 mM KCl/20%o (vol/vol) glycerol/0.1% (vol/vol)
Nonidet P-40/10 ;LM ZnSO4/1 mM dithiothreitol] at 40C for
-
10 min and separated by electrophoresis on a 5% polyacryl-
amide gel in 0.25x TBE buffer (lx TBE buffer = 90 mM
Tris/64.6 mM boric acid/2.5 mM EDTA, pH 8.3).
RESULTS
We have previously shown that the ability to enhance the spi
lects on the phenotype is associated with the mutant E(spl)D gene: trans-
Fig. 1; not genic flies carrying one copy of the mutant gene (m8D) in
DNA from addition to two wild-type copies of the gene show the same
an start site. degree of enhancement of the spi phenotype as do animals
), the HLH bearing the original E(spl)D chromosome (ref. 4; see also Fig.
ded at the C 2B and C). In contrast, transgenic flies containing one or two
the mutated copies of either the corresponding wild-type construct (m8+)
tefnination or the mutant gro gene (m9/mlOD, see Fig. 1A) do not)f the basic
where it has express the spi phenotype in a heterozygous spi background
underlined). (data not shown). In addition, the m9/mlOD transgene fails to
unracterized rescue the lethality associated with a loss-of-function muta-
nd spl eyes tion ofgro (groB4; ref. 25). In this respect, it differs from the
deviation of corresponding wild-type m9/m1O+ fragment, which is capa-
iation of the
ye as a more
ment of the
ng enhance-
f ommatidia
2 B and C
-*, distinct
is present in
ommatidia
o determine
stained from
tested, see
vas obtained
encoding a
1-123 from
). (c and d)
wild-type (c)
acids (d) as
iI sites were
the desired
e two Kpn I
trminal nine
amino acids correspond to those ofthe m8D construct. In g, however,
we demonstrate that these amino acids did not contribute to the
dominant enhancement. (f) For m8+,stOP, different termination
codons were used-TAG, TAA, or TAATAATAA. The protein
represents amino acids 1-123 of the wild-type protein. (g) m8D.8t0P.
This construct encodes the same protein as in f. (h) m&D 6d-. The
protein encoded by this construct is the same as that shown in b,
except that it contains a partially neutralized basic domain. Amino
acid alterations were based on the sequences of either Id (33) or emc
(34, 35), HLH proteins that do not contain a functional basic domain.
(i andj) The proteins encoded by these constructs correspond to the
E(SPL)D protein (b), except that the proline in the basic domain has
been exchanged for either a threonine (m8D.P-T; i) an amino acid
found at this position in all members of the myogenic bHLH family
(see ref. 8 for review), or for an asparagine (m8D.P-N;J), an amino acid
found at this position in proteins ofthe proneural genes ofDrosophila
(36-39), or the proteins ofthe myc family (see ref. 40 for review). For
primers used to create the constructs shown in e-j, see Materials and
Methods. The same primers as in h-j were used to create the
corresponding mutations in the wild-type construct.
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ble of rescuing the embryonic lethality of this or other gro
mutations or the lethality of hemizygous E(spl)D embryos
(ref. 22; H. Schrons, E.K., and J. A. Campos-Ortega, un-
published data). Although we cannot exclude the presence of
minor defects at the amino acid level not detectable by
conventional Southern blot analysis, we suggest that it is the
insertion present in the gro gene on the E(spl)D chromosome
that leads to a partial loss of function of gro. Therefore, we
conclude that the E(spl)D chromosome carries two muta-
tions-one enhances the phenotype of spi and the other
reduces the activity of gro.
As the m8D fragment used earlier carries several lesions
(Fig. 1), we have used different hybrid constructs and mu-
tations for germ-line transformation to localize the region
responsible for the enhancement of spi to the distal part ofthe
mutant E(spl) gene (Fig. 3 a-d). This region carries a deletion
of 483 base pairs, which removes 3' noncoding DNA as well
as a sequence encoding the last 56 amino acids of the
wild-type product, which are replaced by a sequence of 9
amino acids (4) (Fig. 1B). Hence, the mutant phenotype may
be due to (i) truncation of the protein per se, (ii) the additional
amino acid sequence, (iii) deletion of the 3' region of the
transcription unit, (iv) other changes not associated with the
deletion, or (v) any combination of these effects. To exclude
the possibility that other minor sequence differences detected
in the m8D construct (4) might be responsible for this effect,
we reconstructed the same deletion in an m8+ fragment
(m8+.del), which produced the same protein as m8D, and we
obtained the same result as with m8D (Fig. 3e). To distinguish
between the other possibilities, we carried out a set of
manipulations on the m8+ and the m8D constructs and
analyzed their effects on the spi phenotype in transgenic
females (Fig. 3 e-g). Strikingly, although the introduction of
a termination codon at the corresponding position in the
wild-type and mutant genes (m8+ stop and m8DMstoP; Fig. 3 f
and g) should result in production of the same truncated
protein, these two constructs differ significantly in the degree
to which they enhance spi. Whereas one copy of the m8DstoP
construct is sufficient to render spl dominant and thus
behaves like the m8D construct (data not shown), the m8+,stoP
construct gives rise to dominant expression of spI only when
present in two copies (Fig. 2 D and E). Thus the truncation
of the E(SPL) protein is not sufficient to provoke the same
strong enhancement as observed with m8D. As the only
difference between the m8+ ,StOp and m8DstoP constructs re-
sides at the nucleic acid level (see Fig. 3fand g), we conclude
that the DNA, which is deleted in the mutant, carries the
responsible element and we assume that the strong dominant
enhancement of spi is caused by the loss of a regulatory
sequence in the mutant DNA in combination with a trunca-
tion of the protein. This regulatory element could act on
either the transcriptional or the posttranscriptional level-
e.g., by changing the stability of the RNA-but its precise
definition as well as analysis of the molecular basis of its
function await further experiments.
The high degree of amino acid sequence similarity between
the E(SPL) protein and other members of the bHLH class,
which bind via the basic domain to DNA and can activate
transcription (14), led us to assume that the wild-type and
mutant versions of this protein are also involved in DNA
binding. However, the E(SPL) protein as well as all other
members of the E(SPL)-C complex contain a proline residue
in the basic domain (4) at a position where most other bHLH
proteins, except the Drosophila protein hairy (H) (43), con-
tain either a threonine or an asparagine residue. Replacement
of an alanine adjacent to this threonine in the MyoD protein
by a proline has been shown to abolish DNA binding to its
target sequence (15). To address the question of the role of
the basic domain of the E(SPL)D protein, we introduced
various amino acid exchanges (see Material and Methods;
Fig. 3 h-j) and tested their effects on the spi phenotype after
germ-line transformation. In addition, we directly assayed
bacterially expressed wild-type and E(SPL)D protein and
some modified versions of the wild-type protein for their
ability to bind specifically to DNA in vitro. By band-shift
assays, we could demonstrate that both the wild-type and the
E(SPL)D proteins specifically bind to a sequence in the E(spl)
promoter in vitro. Furthermore, DNA binding is totally
abolished after neutralization ofpart ofthe basic domain (Fig.
4). In vivo, neutralization of part of the basic domain of the
E(SPL)D protein (m8D bd-; Fig. 3h) leads to complete loss of
spl-enhancing capacity, suggesting loss of an essential func-
tion of the protein. Replacement of the proline by a threonine
(m8DP-T; Fig. 3i) or asparagine residue (m8DP-N; Fig. 3j), the
two residues that are found at the equivalent position in the
basic domains of most of the other bHLH proteins, results in
only minor modification of the strong spi enhancement: trans-
genic flies carrying the m8DP-N construct exhibit a slightly
stronger enhancement, judged by more severe irregularities of
the ommatidia, those with the m8DP-T construct have a slightly
reduced enhancement compared to those with the m8D con-
struct itself (for assessment of the spi phenotype; see legend
to Fig. 3). Proteins carrying these exchanges [E(SPL)+ P-N and
E(SPL)+ ,P-T] are still able to bind to the specific target se-
quence in vitro (Fig. 4). These results clearly demonstrate that
the basic domains of the E(SPL)+ and E(SPL)D proteins are
functionally important and bind to DNA, despite the presence
of a proline residue, and that neutralization of part of this
domain not only abolishes DNA binding in vitro but also leads
to loss of in vivo function ofthe E(SPL)D protein, as shown by
its inability to enhance the spi phenotype.
DISCUSSION
The bHLH proteins of the E(SPL)-C differ from most of the
other members of this family by the presence of a proline
residue in the basic domain. This has led to speculation as to
whether this domain can function in DNA binding at all, since
a proline residue can confer a kink in a-helical structures (44).
In fact, two HLH proteins without a basic domain have been
competitor
spec. + + + + +
nspec. + + + + +
S S
1 2 3 4 5 5 7 8 9 10 11
FIG. 4. Mobility-shift assay with different versionsof the E(SPL)
protein. The 32P-labeled oligonucleotide, derived from the E(spl)
promoter (4), was incubated without protein (lane 1) or with proteins,
expressed in Escherichia coli and solubilized, renatured, and purified
from inclusion bodies. Lanes: 2 and 3, E(SPL)+; 4 and 5,
E(SPL)+ bd-; 6 and 7, E(SPL)D; 8 and 9, E(SPL)+,P-N; 10 and 11,
E(SPL)+,P-T (designations according to those in Fig. 3). Reactions
were carried out with the same amount of protein in the presence of
either 2 ,ug of unspecific competitor [poly(dI-dC)] (lanes 2, 4, 6, 8, and
10) or 0.5 ug of specific competitor (lanes 3, 5, 7, 9, and 11).
Developmental Biology: Tietze et al.
6156 Developmental Biology: Tietze et al.
described-Id (33) and the protein encoded by the Drosophila
gene emc (34, 35), which are not capable ofDNA binding but
act as negative regulators by forming heterodimers with other
bHLH proteins, thus preventing them from bindingDNA (33,
45). In the case of the bHLH proteins of the E(SPL)-C,
analysis of structure-function relationships is hampered by
the fact that, due to the redundancy of the functions encoded
in this gene complex, no point mutations, apart from the
dominant E(spl)D allele, have ever been found whose effects
would have been indicative of functional domains within the
proteins. To overcome this problem, we designed mutations
in the E(spl) gene and analyzed their effects on the dominant
phenotype. Our results clearly demonstrate the importance
of the basic domain of the E(SPL)D protein for proper
function, since m8D-induced enhancement of the spi pheno-
type and DNA binding are abolished after neutralization of
the basic domain. Recent results have shown that this mutant
version antagonizes the in vitro DNA-binding activity of
wild-type E(SPL) and M5, another bHLH protein of the
E(SPL)-C (N.O. and E.K., unpublished data). This indicates
that it acts as negative regulator in the same way as the
Drosophila EMC or the mouse Id protein (33, 45)-i.e., by
formation of heterodimers that are no longer able to bind to
DNA, probably because two intact basic domains are re-
quired for this process.
Although the in vivo assay (enhancement of the spi phe-
notype) could only be performed with a truncated version of
the E(SPL) protein, we assume that similar conclusions about
the functional importance of the basic domain in vivo can be
applied to the wild-type protein as well. This is particularly
supported by the observation that the wild-type and trun-
cated proteins behave similarly in vitro: both bind to the same
target sequence (cf. Fig. 4). In none of the transgenic stocks
carrying a mutated version of either m8D or m8+ did we
observe any obvious mutant phenotype apart from the en-
hancement of spi. However, further functional assays are
required to determine whether any of the mutant E(SPL)
proteins acts as a dominant negative regulator in vivo, as has
been described for a mutant MyoD protein, in which the basic
domain has been deleted (15).
Strikingly, the binding site of the different forms of the
E(SPL) protein tested here contains not the consensus
CANNTG (E-box) present in the target sites of all other
bHLH proteins described so far but a tandem array of two
slightly divergent motifs (CACGAGCCACAAG). Although
binding to this sequence is specific, as shown by footprinting
assays, a higher affinity is observed with a binding site
containing a canonical E-box motif (N.O. and E.K., unpub-
lished data). However, the different protein versions behaved
essentially in the same way in the presence of either target
site.
So far, we can only speculate about the molecular basis of
the interactions between Notch (N) and its mutant version
split (SPL), a transmembrane protein involved in the trans-
duction of a lateral inhibition signal, and E(SPL), a nuclear
protein involved in mediating this signal and reprogramming
the cell's fate, probably by transcriptional regulation. During
eye development, N is expressed throughout all stages,
whereas E(spl) is specifically expressed in the morphogenic
furrow (19), a region of the eye imaginal disc in which the
founder cells of the ommatidial clusters are determined.
Actually, nothing is known about changes induced in the N
protein in response to the signal, which could include struc-
tural changes of the cytoplasmic domain or the initiation of a
signal transduction cascade, which, in turn, could modulate
the activity ofthe E(SPL) protein in one way or the other. For
example, one can imagine that phosphorylation or structural
modification ofthe E(SPL) protein may induce changes in the
choice of the dimerization partner or binding specificity and
thereby alter the transcription program.
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